Literature DB >> 23089230

Peptidases trimming MHC class I ligands.

Mirjana Weimershaus1, Irini Evnouchidou, Loredana Saveanu, Peter van Endert.   

Abstract

Peptides presented by MHC class I molecules are typically produced through antigen degradation by the proteasome followed by trimming by exopeptidases. According to recent results, these include both aminopeptidases and carboxypeptidases in the cytosol and the endoplasmic reticulum. While cytosolic peptidases have a net neutral or destructive effect on MHC ligands, endoplasmic reticulum aminopeptidases are required for efficient class I loading and have a strong effect on the repertoire of peptide/MHC complexes. Cells lacking these enzymes can be eliminated both by NK cells and by CD8+ T cells recognizing complexes formed between an MHC class Ib molecule and a conserved peptide. Cross-presented peptides derived from internalized antigens can be processed by insulin-regulated aminopeptidase, the only endosomal trimming peptidase.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23089230     DOI: 10.1016/j.coi.2012.10.001

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  29 in total

1.  Screening Identifies Thimerosal as a Selective Inhibitor of Endoplasmic Reticulum Aminopeptidase 1.

Authors:  Athanasios Stamogiannos; Athanasios Papakyriakou; Francois-Xavier Mauvais; Peter van Endert; Efstratios Stratikos
Journal:  ACS Med Chem Lett       Date:  2016-05-31       Impact factor: 4.345

2.  Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1).

Authors:  Despoina Koumantou; Eilon Barnea; Adrian Martin-Esteban; Zachary Maben; Athanasios Papakyriakou; Anastasia Mpakali; Paraskevi Kokkala; Harris Pratsinis; Dimitris Georgiadis; Lawrence J Stern; Arie Admon; Efstratios Stratikos
Journal:  Cancer Immunol Immunother       Date:  2019-06-20       Impact factor: 6.968

3.  Automated benchmarking of peptide-MHC class I binding predictions.

Authors:  Thomas Trolle; Imir G Metushi; Jason A Greenbaum; Yohan Kim; John Sidney; Ole Lund; Alessandro Sette; Bjoern Peters; Morten Nielsen
Journal:  Bioinformatics       Date:  2015-02-25       Impact factor: 6.937

4.  Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition.

Authors:  Yosuke Shionoya; Takayuki Kanaseki; Sho Miyamoto; Serina Tokita; Ayumi Hongo; Yasuhiro Kikuchi; Vitaly Kochin; Kazue Watanabe; Ryota Horibe; Hiroshi Saijo; Tomohide Tsukahara; Yoshihiko Hirohashi; Hiroki Takahashi; Noriyuki Sato; Toshihiko Torigoe
Journal:  Oncoimmunology       Date:  2017-01-03       Impact factor: 8.110

5.  Critical Role of Interdomain Interactions in the Conformational Change and Catalytic Mechanism of Endoplasmic Reticulum Aminopeptidase 1.

Authors:  Athanasios Stamogiannos; Zachary Maben; Athanasios Papakyriakou; Anastasia Mpakali; Paraskevi Kokkala; Dimitris Georgiadis; Lawrence J Stern; Efstratios Stratikos
Journal:  Biochemistry       Date:  2017-03-02       Impact factor: 3.162

6.  Mechanism for antigenic peptide selection by endoplasmic reticulum aminopeptidase 1.

Authors:  Petros Giastas; Anastasia Mpakali; Athanasios Papakyriakou; Aggelos Lelis; Paraskevi Kokkala; Margarete Neu; Paul Rowland; John Liddle; Dimitris Georgiadis; Efstratios Stratikos
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-16       Impact factor: 11.205

Review 7.  Antigenic peptide trimming by ER aminopeptidases--insights from structural studies.

Authors:  Efstratios Stratikos; Lawrence J Stern
Journal:  Mol Immunol       Date:  2013-03-29       Impact factor: 4.407

Review 8.  Regulation of the Cell Biology of Antigen Cross-Presentation.

Authors:  J Magarian Blander
Journal:  Annu Rev Immunol       Date:  2018-02-28       Impact factor: 28.527

9.  Structural Basis for Antigenic Peptide Recognition and Processing by Endoplasmic Reticulum (ER) Aminopeptidase 2.

Authors:  Anastasia Mpakali; Petros Giastas; Nikolas Mathioudakis; Irene M Mavridis; Emmanuel Saridakis; Efstratios Stratikos
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

10.  Getting personal with neoantigen-based therapeutic cancer vaccines.

Authors:  Nir Hacohen; Edward F Fritsch; Todd A Carter; Eric S Lander; Catherine J Wu
Journal:  Cancer Immunol Res       Date:  2013-04-07       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.